Riera M, De la Fuente L, Gallego O, Ribas MA, Leyes M, Soriano V, Salas A; International Conference on AIDS.

Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. C10669.

Hospital Son Dureta, Palma, Spain

BACKGROUND: To measure the variables related with virological failure in an HIV cohort with drug levels, adherence and drug-resistance genotyping assessment. METHODS: Prospective, observational study of 143 consecutive patients with HIV infection who are receiving antiretroviral treatment, followed during 9 months. The adherence was assessed by pill count and drug plasma levels every three months. The CD4 and viral load was also measured at baseline and every three months, and we consider virological failure when the two last viral load were>500 copies/ml. The resistance mutations in protease and reverse-transcripts genes were performed. RESULTS: 55 patients (38,5%) at the end of the study present a good virological control, 54 (37,7%) were in virological failure, and 34 (23%) were excluded because some viral load was > 500 copies/ml. The variables associated with virological failure in univariate logistic regression analysis are: Adherence by gold-standard OR: 2.34 (1.02-5.2), HIV acquisition not related with homosexual (HSX) practices OR 4.16 (1.5-11.4), to be in treatment with two or four antiretroviral drugs vs. triple therapy OR: 3.42 (1.3-9), indinavir, but not lamivudine or ritonavir plasma levels, OR 5.2(1.26-21.7), age, viral load and protease and reverse-transcripts resistance related mutations at baseline. Higher baseline plasma viral load OR: 2.16(1.65-2.85) and non-HSX related HIV acquisition OR: 3.8(1.1-13.1) were the only factors included in the multivariate analysis. CONCLUSIONS: Baseline plasma viral load and factors related with adherence are the principal predictors of virological failure.

Publication Types:

• Meeting Abstracts

Keywords:

• Acquired Immunodeficiency Syndrome
• Antiretroviral Therapy, Highly Active
• Drug Therapy, Combination
• HIV Infections
• HIV Seropositivity
• Humans
• Indinavir
• Lamivudine
• Prospective Studies
• Ritonavir
• Viral Load
• drug therapy
• therapy
• virology

Other ID:

• GWAIDS0017492

UI: 102254990

From Meeting Abstracts